Clinical Trial Update: Safety and Efficacy of Fingolimod in MS Patients in China [Phase 3]

View source ↗

Summary

Clinical trial of fingolimod in relapsing-remitting multiple sclerosis in China was withdrawn during Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis (Relapsing Remitting) | Phase 3 | Status: WITHDRAWN